Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904294860> ?p ?o ?g. }
- W2904294860 endingPage "73" @default.
- W2904294860 startingPage "57" @default.
- W2904294860 abstract "BackgroundPatients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting has been inconsistent between individual studies. Minimal data are available on the effect of maintenance lenalidomide in more aggressive disease states, such as patients with cytogenetic high-risk disease or patients ineligible for transplantation. We aimed to assess lenalidomide maintenance versus observation in patients with newly diagnosed multiple myeloma, including cytogenetic risk and transplantation status subgroup analyses.MethodsThe Myeloma XI trial was an open-label, randomised, phase 3, adaptive design trial with three randomisation stages done at 110 National Health Service hospitals in England, Wales, and Scotland. There were three potential randomisations in the study: induction treatment (allocation by transplantation eligibility status); intensification treatment (allocation by response to induction therapy); and maintenance treatment. Here, we report the results of the randomisation to maintenance treatment. Eligible patients for maintenance randomisation were aged 18 years or older and had symptomatic or non-secretory multiple myeloma, had completed their assigned induction therapy as per protocol and had achieved at least a minimal response to protocol treatment, including lenalidomide. Patients were randomly assigned (1:1 from Jan 13, 2011, to Jun 27, 2013, and 2:1 from Jun 28, 2013, to Aug 11, 2017) to lenalidomide maintenance (10 mg orally on days 1–21 of a 28-day cycle) or observation, and stratified by allocated induction and intensification treatment, and centre. The co-primary endpoints were progression-free survival and overall survival, analysed by intention to treat. Safety analysis was per protocol. This study is registered with the ISRCTN registry, number ISRCTN49407852, and clinicaltrialsregister.eu, number 2009-010956-93, and has completed recruitment.FindingsBetween Jan 13, 2011, and Aug 11, 2017, 1917 patients were accrued to the maintenance treatment randomisation of the trial. 1137 patients were assigned to lenalidomide maintenance and 834 patients to observation. After a median follow-up of 31 months (IQR 18–50), median progression-free survival was 39 months (95% CI 36–42) with lenalidomide and 20 months (18–22) with observation (hazard ratio [HR] 0·46 [95% CI 0·41–0·53]; p<0·0001), and 3-year overall survival was 78·6% (95% Cl 75·6–81·6) in the lenalidomide group and 75·8% (72·4–79·2) in the observation group (HR 0·87 [95% CI 0·73–1·05]; p=0·15). Progression-free survival was improved with lenalidomide compared with observation across all prespecified subgroups. On prespecified subgroup analyses by transplantation status, 3-year overall survival in transplantation-eligible patients was 87·5% (95% Cl 84·3–90·7) in the lenalidomide group and 80·2% (76·0–84·4) in the observation group (HR 0·69 [95% CI 0·52–0·93]; p=0·014), and in transplantation-ineligible patients it was 66·8% (61·6–72·1) in the lenalidomide group and 69·8% (64·4–75·2) in the observation group (1·02 [0·80–1·29]; p=0·88). By cytogenetic risk group, in standard-risk patients, 3-year overall survival was 86·4% (95% CI 80·0–90·9) in the lenalidomide group compared with 81·3% (74·2–86·7) in the observation group, and in high-risk patients, it was 74.9% (65·8–81·9) in the lenalidomide group compared with 63·7% (52·8–72·7) in the observation group; and in ultra-high-risk patients it was 62·9% (46·0–75·8) compared with 43·5% (22·2–63·1). Since these subgroup analyses results were not powered they should be interpreted with caution. The most common grade 3 or 4 adverse events for patients taking lenalidomide were haematological, including neutropenia (362 [33%] patients), thrombocytopenia (72 [7%] patients), and anaemia (42 [4%] patients). Serious adverse events were reported in 494 (45%) of 1097 patients receiving lenalidomide compared with 150 (17%) of 874 patients on observation. The most common serious adverse events were infections in both the lenalidomide group and the observation group. 460 deaths occurred during maintenance treatment, 234 (21%) in the lenalidomide group and 226 (27%) in the observation group, and no deaths in the lenalidomide group were deemed treatment related.InterpretationMaintenance therapy with lenalidomide significantly improved progression-free survival in patients with newly diagnosed multiple myeloma compared with observation, but did not improve overall survival in the intention-to-treat analysis of the whole trial population. The manageable safety profile of this drug and the encouraging results in subgroup analyses of patients across all cytogenetic risk groups support further investigation of maintenance lenalidomide in this setting.FundingCancer Research UK, Celgene, Amgen, Merck, and Myeloma UK. Patients with multiple myeloma treated with lenalidomide maintenance therapy have improved progression-free survival, primarily following autologous stem-cell transplantation. A beneficial effect of lenalidomide maintenance therapy on overall survival in this setting has been inconsistent between individual studies. Minimal data are available on the effect of maintenance lenalidomide in more aggressive disease states, such as patients with cytogenetic high-risk disease or patients ineligible for transplantation. We aimed to assess lenalidomide maintenance versus observation in patients with newly diagnosed multiple myeloma, including cytogenetic risk and transplantation status subgroup analyses. The Myeloma XI trial was an open-label, randomised, phase 3, adaptive design trial with three randomisation stages done at 110 National Health Service hospitals in England, Wales, and Scotland. There were three potential randomisations in the study: induction treatment (allocation by transplantation eligibility status); intensification treatment (allocation by response to induction therapy); and maintenance treatment. Here, we report the results of the randomisation to maintenance treatment. Eligible patients for maintenance randomisation were aged 18 years or older and had symptomatic or non-secretory multiple myeloma, had completed their assigned induction therapy as per protocol and had achieved at least a minimal response to protocol treatment, including lenalidomide. Patients were randomly assigned (1:1 from Jan 13, 2011, to Jun 27, 2013, and 2:1 from Jun 28, 2013, to Aug 11, 2017) to lenalidomide maintenance (10 mg orally on days 1–21 of a 28-day cycle) or observation, and stratified by allocated induction and intensification treatment, and centre. The co-primary endpoints were progression-free survival and overall survival, analysed by intention to treat. Safety analysis was per protocol. This study is registered with the ISRCTN registry, number ISRCTN49407852, and clinicaltrialsregister.eu, number 2009-010956-93, and has completed recruitment. Between Jan 13, 2011, and Aug 11, 2017, 1917 patients were accrued to the maintenance treatment randomisation of the trial. 1137 patients were assigned to lenalidomide maintenance and 834 patients to observation. After a median follow-up of 31 months (IQR 18–50), median progression-free survival was 39 months (95% CI 36–42) with lenalidomide and 20 months (18–22) with observation (hazard ratio [HR] 0·46 [95% CI 0·41–0·53]; p<0·0001), and 3-year overall survival was 78·6% (95% Cl 75·6–81·6) in the lenalidomide group and 75·8% (72·4–79·2) in the observation group (HR 0·87 [95% CI 0·73–1·05]; p=0·15). Progression-free survival was improved with lenalidomide compared with observation across all prespecified subgroups. On prespecified subgroup analyses by transplantation status, 3-year overall survival in transplantation-eligible patients was 87·5% (95% Cl 84·3–90·7) in the lenalidomide group and 80·2% (76·0–84·4) in the observation group (HR 0·69 [95% CI 0·52–0·93]; p=0·014), and in transplantation-ineligible patients it was 66·8% (61·6–72·1) in the lenalidomide group and 69·8% (64·4–75·2) in the observation group (1·02 [0·80–1·29]; p=0·88). By cytogenetic risk group, in standard-risk patients, 3-year overall survival was 86·4% (95% CI 80·0–90·9) in the lenalidomide group compared with 81·3% (74·2–86·7) in the observation group, and in high-risk patients, it was 74.9% (65·8–81·9) in the lenalidomide group compared with 63·7% (52·8–72·7) in the observation group; and in ultra-high-risk patients it was 62·9% (46·0–75·8) compared with 43·5% (22·2–63·1). Since these subgroup analyses results were not powered they should be interpreted with caution. The most common grade 3 or 4 adverse events for patients taking lenalidomide were haematological, including neutropenia (362 [33%] patients), thrombocytopenia (72 [7%] patients), and anaemia (42 [4%] patients). Serious adverse events were reported in 494 (45%) of 1097 patients receiving lenalidomide compared with 150 (17%) of 874 patients on observation. The most common serious adverse events were infections in both the lenalidomide group and the observation group. 460 deaths occurred during maintenance treatment, 234 (21%) in the lenalidomide group and 226 (27%) in the observation group, and no deaths in the lenalidomide group were deemed treatment related. Maintenance therapy with lenalidomide significantly improved progression-free survival in patients with newly diagnosed multiple myeloma compared with observation, but did not improve overall survival in the intention-to-treat analysis of the whole trial population. The manageable safety profile of this drug and the encouraging results in subgroup analyses of patients across all cytogenetic risk groups support further investigation of maintenance lenalidomide in this setting." @default.
- W2904294860 created "2018-12-22" @default.
- W2904294860 creator A5008572050 @default.
- W2904294860 creator A5016246851 @default.
- W2904294860 creator A5017165070 @default.
- W2904294860 creator A5027075405 @default.
- W2904294860 creator A5027410624 @default.
- W2904294860 creator A5032055781 @default.
- W2904294860 creator A5033344593 @default.
- W2904294860 creator A5034560778 @default.
- W2904294860 creator A5035489508 @default.
- W2904294860 creator A5038580329 @default.
- W2904294860 creator A5042419236 @default.
- W2904294860 creator A5058317897 @default.
- W2904294860 creator A5063301766 @default.
- W2904294860 creator A5064080209 @default.
- W2904294860 creator A5070244650 @default.
- W2904294860 creator A5072977279 @default.
- W2904294860 creator A5073477610 @default.
- W2904294860 creator A5073907684 @default.
- W2904294860 creator A5075027197 @default.
- W2904294860 creator A5081247376 @default.
- W2904294860 creator A5083949340 @default.
- W2904294860 date "2019-01-01" @default.
- W2904294860 modified "2023-10-13" @default.
- W2904294860 title "Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial" @default.
- W2904294860 cites W1527383154 @default.
- W2904294860 cites W1567787789 @default.
- W2904294860 cites W1795880523 @default.
- W2904294860 cites W1974656498 @default.
- W2904294860 cites W1995548777 @default.
- W2904294860 cites W2003734726 @default.
- W2904294860 cites W2015345028 @default.
- W2904294860 cites W2018729528 @default.
- W2904294860 cites W2026448323 @default.
- W2904294860 cites W2044436186 @default.
- W2904294860 cites W2046408556 @default.
- W2904294860 cites W2055662838 @default.
- W2904294860 cites W2066713758 @default.
- W2904294860 cites W2093757149 @default.
- W2904294860 cites W2104993929 @default.
- W2904294860 cites W2114217833 @default.
- W2904294860 cites W2119810076 @default.
- W2904294860 cites W2125477622 @default.
- W2904294860 cites W2125721471 @default.
- W2904294860 cites W2128084036 @default.
- W2904294860 cites W2128192762 @default.
- W2904294860 cites W2136373453 @default.
- W2904294860 cites W2141105112 @default.
- W2904294860 cites W2143425592 @default.
- W2904294860 cites W2318069817 @default.
- W2904294860 cites W2465273882 @default.
- W2904294860 cites W2560592054 @default.
- W2904294860 cites W2586628510 @default.
- W2904294860 cites W2622796688 @default.
- W2904294860 cites W2737964630 @default.
- W2904294860 cites W2747215423 @default.
- W2904294860 doi "https://doi.org/10.1016/s1470-2045(18)30687-9" @default.
- W2904294860 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6318225" @default.
- W2904294860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30559051" @default.
- W2904294860 hasPublicationYear "2019" @default.
- W2904294860 type Work @default.
- W2904294860 sameAs 2904294860 @default.
- W2904294860 citedByCount "224" @default.
- W2904294860 countsByYear W29042948602019 @default.
- W2904294860 countsByYear W29042948602020 @default.
- W2904294860 countsByYear W29042948602021 @default.
- W2904294860 countsByYear W29042948602022 @default.
- W2904294860 countsByYear W29042948602023 @default.
- W2904294860 crossrefType "journal-article" @default.
- W2904294860 hasAuthorship W2904294860A5008572050 @default.
- W2904294860 hasAuthorship W2904294860A5016246851 @default.
- W2904294860 hasAuthorship W2904294860A5017165070 @default.
- W2904294860 hasAuthorship W2904294860A5027075405 @default.
- W2904294860 hasAuthorship W2904294860A5027410624 @default.
- W2904294860 hasAuthorship W2904294860A5032055781 @default.
- W2904294860 hasAuthorship W2904294860A5033344593 @default.
- W2904294860 hasAuthorship W2904294860A5034560778 @default.
- W2904294860 hasAuthorship W2904294860A5035489508 @default.
- W2904294860 hasAuthorship W2904294860A5038580329 @default.
- W2904294860 hasAuthorship W2904294860A5042419236 @default.
- W2904294860 hasAuthorship W2904294860A5058317897 @default.
- W2904294860 hasAuthorship W2904294860A5063301766 @default.
- W2904294860 hasAuthorship W2904294860A5064080209 @default.
- W2904294860 hasAuthorship W2904294860A5070244650 @default.
- W2904294860 hasAuthorship W2904294860A5072977279 @default.
- W2904294860 hasAuthorship W2904294860A5073477610 @default.
- W2904294860 hasAuthorship W2904294860A5073907684 @default.
- W2904294860 hasAuthorship W2904294860A5075027197 @default.
- W2904294860 hasAuthorship W2904294860A5081247376 @default.
- W2904294860 hasAuthorship W2904294860A5083949340 @default.
- W2904294860 hasBestOaLocation W29042948601 @default.
- W2904294860 hasConcept C126322002 @default.
- W2904294860 hasConcept C143998085 @default.
- W2904294860 hasConcept C2776063141 @default.
- W2904294860 hasConcept C2776364478 @default.
- W2904294860 hasConcept C2779609412 @default.
- W2904294860 hasConcept C3019800554 @default.